Na Ra
Na Ra Han, Changwon KR
Patent application number | Description | Published |
---|---|---|
20110243775 | SCROLL COMPRESSOR - A scroll compressor is provided. A value obtained by multiplying a wrap height (H) by a driving speed (V) may be controlled to be within a range of approximately 500˜1000 mmHz at a low speed driving (less than approximately 35 Hz). The wrap height of the scroll compressor, and the driving speed may be set to be optimum, thereby preventing the scroll compressor from being operated at a speed excessively lower or higher than a predetermined driving speed. This may allow the scroll compressor to be operated at an optimum low speed corresponding to the wrap height, and thus, the compressor and a refrigerating cycle apparatus having the same may have enhanced performances. | 10-06-2011 |
Na Ra Jeon, Gangneung-Si KR
Patent application number | Description | Published |
---|---|---|
20110206784 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL SYNDROME CONTAINING EXTRACTS OR FRACTIONS OF ACERIPHYLLUM ROSSII AS AN EFFECTIVE INGREDIENT - The present invention relates to a method for the prevention and treatment of postmenopausal syndrome containing the step of administering a pharmaceutically effective dose of the | 08-25-2011 |
Na Ra Kim, Gyeonggi-Do KR
Patent application number | Description | Published |
---|---|---|
20120190634 | LIPOTEICHOIC ACID-DERIVED GLYCOLIPIDS, AND COMPOSITIONS COMPRISING SAME - A lipoteichoic acid (LTA)-derived glycolipid, and a pharmaceutical, food or cosmetic composition and a vaccine adjuvant including the same are provided. The LTA-derived glycolipid can inhibit the production of inflammatory cytokines and thus have anti-inflammatory effects. Therefore, the pharmaceutical, food or cosmetic compositions including the LTA-derived glycolipid can be used to prevent and treat inflammatory diseases, and the LTA-derived glycolipid can be also used as the vaccine adjuvant. | 07-26-2012 |
Na Ra Kwon, Seoul KR
Patent application number | Description | Published |
---|---|---|
20110003342 | INOSINE PRODUCING MICROORGANISM BELONGING TO THE GENUS CORYNEBACTERIUM AND PROCESS OF PRODUCING INOSINE USING THE SAME - A microorganism of the genus | 01-06-2011 |
20120021466 | Microorganisms of Corynebacterium with Improved 5'-Inosinic Acid Productivity, and Method for Producing Nucleic Acids Using Same - The present invention relates to a microorganisms of the genus | 01-26-2012 |
Na Ra Shin, Seoul KR
Patent application number | Description | Published |
---|---|---|
20160087219 | LIGHT STABILIZER, ORGANIC PHOTOVOLTAIC CELL CONTAINING THE SAME AND METHOD FOR PREPARING THE SAME - The present disclosure relates to an additive for improving the light stability of a conjugated polymer, a method for preparing the same and an organic photovoltaic cell containing the same. Since the additive of the present disclosure improves the light stability of a conjugated polymer, it can be used for an organic photovoltaic (OPV) cell device and can also be usefully used for an organic optoelectronic device using a conductive polymer, such as an organic photodiode (OPD), an organic thin-film transistor (OTFT), an organic light-emitting diode (OLED), etc. | 03-24-2016 |
Na Ra Yoon, Seoul KR
Patent application number | Description | Published |
---|---|---|
20160060312 | Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Pancreatic Cancer Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Pancreatic Cancer Compositions Comprising the Same - In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance. Protein transduction exploits the ability of some cell-penetrating peptide (CPP) sequences to enhance the uptake of proteins and other macromolecules by mammalian cells. Previously developed hydrophobic CPPs, named membrane translocating sequence (MTS), membrane translocating motif (MTM) and macromolecule transduction domain (MTD), are able to deliver biologically active proteins into a variety of cells and tissues. Various cargo proteins fused to these CPPs have been used to test the functional and/or therapeutic efficacy of protein transduction. The recombinant proteins consisting of suppressor of cytokine signaling 3 (CP-SOCS3) protein fused to the fibroblast growth factor (FGF) 4-derived MTM were developed to inhibit inflammation and apoptosis. However, CP-SOCS3 fusion proteins expressed in bacteria cells were hard to be purified in soluble form. To address these critical limitations, CPP sequences called advanced MTDs (aMTDs) have been developed in this art. This is accomplished by (i) analyzing previous developed hydrophobic CPP sequences to identify specific critical factors (CFs) that affect intracellular delivery potential and (ii) constructing artificial aMTD sequences that satisfy each critical factor. In addition, solubilization domains (SDs) have been incorporated into the aMTD-fused SOCS3 recombinant proteins to enhance solubility with corresponding increases in protein yield and cell-/tissue-permeability. These recombinant SOCS3 proteins fused to aMTD/SD having much higher solubility/yield and cell-/tissue-permeability have been named as improved cell-permeable SOCS3 (iCP-SOCS3) proteins. Previously developed CP-SOCS3 proteins fused to MTM were only tested or used as anti-inflammatory agents to treat acute liver injury. In the present art, iCP-SOCS3 proteins have been tested for use as anti-cancer agents in the treatment of pancreatic cancer. Since SOCS3 is frequently deleted in cancer cells and loss of SOCS3 promotes resistance to apoptosis and proliferation, we reasoned that iCP-SOCS3 could be used as a protein-based intracellular replacement therapy for the treatment of pancreatic cancer. The results demonstrated in this art support this reasoning: treatment of pancreatic cancer cells with iCP-SOCS3 results in reduced cancer cell viability, enhanced apoptosis and loss of cell migration/invasion potentials. Furthermore, iCP-SOCS3 inhibits the growth of pancreatic cancer in a subcutaneous xenografts model. In the present invention with iCP-SOCS3, where SOCS3 is fused to an empirically determined combination of newly developed aMTD and customized SD, macromolecule intracellular transduction technology (MITT) enabled by the advanced MTDs may provide novel protein therapy against pancreatic cancer. | 03-03-2016 |
Na-Ra Kim, Seongnam-Si KR
Patent application number | Description | Published |
---|---|---|
20140110786 | SEMICONDUCTOR DEVICE HAVING BURIED CHANNEL ARRAY - A semiconductor device includes a field regions in a substrate to define active regions, gate trenches including active trenches disposed across the active region and field trenches in the field regions, and word lines that fill the gate trenches and extend in a first direction. The word lines include active gate electrodes occupying the active trenches, and field gate electrodes occupying the field trenches. The bottom surface of each field gate electrode, which is disposed between active regions that are adjacent to each other and have one word line therebetween, is disposed at a higher level than the bottom surfaces of the active gate electrodes. | 04-24-2014 |
20140362637 | MEMORY DEVICE, MEMORY SYSTEM, AND OPERATION METHOD THEREOF - A memory device comprises: a memory cell array comprising first and second word lines located adjacent to each other, a first memory cell connected to the first word line, and a second memory cell connected to the second word line and located adjacent to the first memory cell; and a word line voltage supplying unit that transitions a word line voltage of the first word line from a first word line voltage to a second word line voltage, in response to a first control signal. A transition control unit generates the first control signal for controlling a pulse of the word line voltage of the first word line in a transition period from the first word line voltage to the second word line voltage in such a way that a transition waveform profile from the first word line voltage to the second word line voltage is different from a transition waveform profile from the second word line voltage to the first word line voltage. | 12-11-2014 |
20150263113 | SEMICONDUCTOR DEVICE HAVING BURIED CHANNEL ARRAY - A semiconductor device includes a field regions in a substrate to define active regions, gate trenches including active trenches disposed across the active region and field trenches in the field regions, and word lines that fill the gate trenches and extend in a first direction. The word lines include active gate electrodes occupying the active trenches, and field gate electrodes occupying the field trenches. The bottom surface of each field gate electrode, which is disposed between active regions that are adjacent to each other and have one word line therebetween, is disposed at a higher level than the bottom surfaces of the active gate electrodes. | 09-17-2015 |
Na-Ra Lee, Gyeonggi-Do KR
Patent application number | Description | Published |
---|---|---|
20130108542 | Method for MN3O4 nanoparticles by solid-state decomposition of exfoliated MNO2 nanosheet | 05-02-2013 |
Na-Ra Park, Seoul KR
Patent application number | Description | Published |
---|---|---|
20140108164 | DIALOG BOX MANAGEMENT SYSTEM, USER TERMINAL, DIALOG BOX EXPOSURE METHOD AND METHOD FOR CONFIGURING DIALOG BOX EXPOSURE USING THE SAME - A dialog box management system, a user system, a dialog box exposure method and a method for configuring dialog box exposure using the same are provided. The dialog box management system includes a communication unit which receives one or more information among application information, mobile web information, and dialog box management information from a registrant terminal registering applications or mobile webs, transmits a dialog box control program to the registrant terminal, and transmits dialog box management information for each application or dialog box management information for each mobile web to a user terminal executing applications or accessing mobile webs; an information management unit which registers and manages the dialog box management information for application or the dialog box management information for each mobile web; and a unit for managing a dialog box control program which manages the dialog box control program. | 04-17-2014 |